EL7.AI
StocksMediumUpdated•Originally published 16 April 2026•Updated 17 April 2026•
1 min read

Lexaria Bioscience Initiates New Animal Study to Expand GLP-1 Intellectual Property Portfolio

Key Facts

1Lexaria Bioscience signed contracts with a CRO to execute animal Study #1 (GLP-1-A26-1).
2The study will evaluate DehydraTECH-semaglutide and DehydraTECH-CBD formulations to improve performance and stake new IP claims.
3Dosing is expected to begin within approximately 60 days.

Lexaria Bioscience (Nasdaq: LEXX) has initiated a new animal study to evaluate DehydraTECH-semaglutide and DehydraTECH-CBD formulations, aiming to enhance drug delivery and secure new intellectual property. This development coincides with the US FDA's approval of Eli Lilly's Foundayo (orforglipron), an oral GLP-1 agonist tablet for obesity management. Lexaria CEO Richard Christopher stated that the expansion of the oral weight-loss drug category significantly increases partnership opportunities for the company's proprietary DehydraTECH technology. By leveraging its drug delivery platform, Lexaria aims to capitalize on the market shift toward oral treatments in the competitive GLP-1 sector. Investors are closely monitoring these advancements for their potential to improve drug efficacy and boost the value of the company's scientific assets. This strategic move underscores Lexaria's commitment to advancing innovative biotech solutions amid a rapidly growing market for diabetes and weight-loss therapies.